Autopsy report · NCT01000896

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

“AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Cancer; Non Small Cell Lung Cancer; Epithelial Ovarian Cancer

Interventions

AZD0530; Carboplatin; paclitaxel

Participants

27 (planned, not actual)

Sites

2

Countries

Japan

Trials that died the same way

• Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
  “Manufacturer AstraZeneca withdrew the study due to lack of funding” (67% match in meaning)
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
  “Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice” (62% match in meaning)
• Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
  “AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.